The potential of a 2Tone trainer to help patients use their metered-dose inhalers

Chest

Volumn 131, Issue 6, 2007, Pages 1776-1782

  Al Showair, Raid A M ^a   Pearson, Stanley B ^b   Chrystyn, Henry ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

2Tone trainer; Asthma quality of life; Metered close inhaler; Slow inhalation rate

Indexed keywords

CORTICOSTEROID;

ADULT; ARTICLE; ASTHMA; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; JUNIPER ASTHMA QUALITY OF LIFE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; METERED DOSE INHALER; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TECHNIQUE; TRAINING; UNITED KINGDOM; VERBAL COMMUNICATION;

EID: 34250796234     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.06-2765     Document Type: Article

References (34)

1. Paterson IC, Crompton GK. Use of pressurized aerosols by asthmatic patients. BMJ 1976; 1:76-77
2. Crompton GK. Problems patients have using their pressurised aerosol inhalers. Eur J Respir Dis 1982; 63(suppl): 101-104
3. Pederson S, Frost L, Arnfred T. Errors in inhalation technique and efficiency in inhaler use in asthmatic children. Allergy 1986; 41:118-124
4. Larsen JS, Hahn M, Ekholm B, et al. Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients. J Asthma 1994; 31:193-199
5. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir Med 2000; 94:496-500
6. Lahdensuo A, Muittari A. Bronchodilator effects of a fenoterol metered dose inhaler and fenoterol powder in asthmatics with poor inhaler technique. Eur J Respir Dis 1986; 68:332-335
7. Horsley MG, Bailie GR. Risk factors for inadequate use of pressurized aerosol inhalers. J Clin Pharm Ther 1998; 13:139-143
8. Orehek J, Gayrard P, Grimaud C, et al. Patient error in use of bronchodilator metered aerosols. BMJ 1976; 1:76
9. Tomlinson HS, Corlett SA, Allen MB, et al. Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge. Br J Clin Pharmacol 2005; 60:605-610
10. Newman SP, Pavia D, Garland SP, et al. Effects of various inhalation modes on deposition of radioactive pressurised aerosols. Eur J Respir Dis 1982; 63(suppl):57-69
11. Newman SP, Steed K, Hooper G, et al. Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered dose inhaler. Pharm Res 1995; 12:231-236
12. Ressor Nimmo CJ, Chen DNM, Martinusen SM, et al. Assessment of patient acceptance and inhalation technique of a pressurized aerosol inhaler and two breath-actuated devices. Ann Pharmacother 1993; 27:922-927
13. Hesselink AE, Penninx BWJH, Wijnboven HAH, et al. Determinants of an incorrect inhalation technique in patients with asthma and COPD. Scand J Prim Health Care 2001; 19:255-260
14. Pauwels R, Newman S, Borgstrom L. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur Respir J 1997; 10:2127-2138
15. Chrystyn H, Brownlee K, Chetcuti P, et al. Inhalation rates of asthmatic children (child) and adults and of chronic obstructive pulmonary disease (COPD) patients through inhalers [abstract]. Am J Respir Crit Care Med 2002; 105(suppl):A190
16. Breeders MEAC, Molema J, Hop WC, et al. Inhalation profiles in asthmatic and COPD patients: reproducibility and effect of instruction. J Aerosol Med 2003; 16:131-141
17. Shim C, Williams MH. The adequacy of inhalation of aerosol from canister nebulizers. Am J Med 1980; 891-894
18. Juniper EF, Guyatt GH, Cox FM, et al. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999; 14:32-38
19. Hindle M, Newton DAG, Chrystyn H. Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Thorax 1993; 48:607-610
20. Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001; 5:1-149
21. Dolovich MB, Ahrens MB, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005; 127:335-371
22. Farr SJ, Rowe AM, Rubsamen R, et al. Aerosol deposition in the human lung following administration from a microprocessor controlled pressurised metered dose inhaler. Thorax 1995; 50:639-644
23. 2-agonist particle size. Am J Respir Crit Care Med 2005; 172:1497-1504
24. Carstairs JR, Nimmo AJ, Barnes BJ. Autoradiographic visualisation of β-adrenoceptor subtype in human lung. Am Rev Respir Dis 1985; 132:541-547
25. Kraft M, Djukanovic R, Wilson S, et al. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154:150.5-1510
26. Rand Sutherland E, Martin RJ, Bowler RP, et al. Physiologic correlates of distal lung inflammation in asthma. J Allergy Clin Immunol 2004; 113:1046-1050
27. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclometasone. Eur Respir J 1998; 12:1346-1353
28. Juniper EF, Price DB, Stampone PA, et al. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest 2002; 121:1824-1832
29. Gonzalez-Martin G, Joo I, Sanchez I. Evaluation of the impact of a pharmaceutical care program in children with asthma. Patient Educ Couns 2003; 49:13-18
30. Rowe BH, Oxman AD. Performance of an asthma quality of life questionnaire in an outpatient setting. Am Rev Respir Dis 1993; 148:675-681
31. Stahl E, Postma DS, Juniper EF, et al. Health-related quality of life in asthma studies: can we combine data from different countries? Pulm Pharmacol Ther 2003; 16:53-59
32. Juniper EF, Guyatt GH, Epstein RD, et al. Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47:76-83
33. Juniper EF, Guayatt GH, Ferrie PJ, et al. Measuring quality of life in asthma. Am Rev Respir Dis 1993; 147:832-838
34. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in disease-specific quality of life instrument. J Clin Epidemiol 1994; 102:16-17